Stocks and Investing Stocks and Investing
Wed, September 4, 2019
Tue, September 3, 2019

Paul Matteis Maintained (ACAD) at Hold with Increased Target to $28 on, Sep 3rd, 2019


Published on 2024-10-26 15:54:31 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $24 to $28 on, Sep 3rd, 2019.

Paul has made no other calls on ACAD in the last 4 months.



There are 2 other peers that have a rating on ACAD. Out of the 2 peers that are also analyzing ACAD, 0 agree with Paul's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Paul


  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $40 on, Tuesday, August 27th, 2019
  • Danielle Brill of "Raymond James" Reiterated at Strong Buy with Increased Target to $43 on, Friday, May 31st, 2019

Contributing Sources